Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI biotechnology company whose news flow centers on AI-driven biologics discovery, vaccine research and therapeutic programs. Public announcements describe a platform built on patented HYFT patterns and the LensAI software environment, combining in silico analysis with an integrated wet lab to advance drug discovery and development.
News about MindWalk often highlights progress in specific programs. The company has reported advances in a universal influenza program, stating that HYFT Deep Data technology identified a functional constraint that persists across influenza A and B viruses, including human, avian and swine-associated datasets. It has also issued updates on an AI-designed GLP-1 receptor agonist program and a proposed dual-pathway regimen that links GLP-1 biology to a second, longevity-related pathway, as well as a universal dengue vaccine initiative built around a conserved discontinuous epitope.
In neurodegeneration, MindWalk has announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in ALS, FTD and certain forms of Alzheimer’s disease. Additional releases cover financial results, strategic divestitures, share repurchase authorizations, at-the-market equity facilities and leadership appointments, reflecting both scientific and corporate developments.
Investors and observers using this news page can review company-issued press releases on Bio-Native AI platform advances, program milestones, capital markets activity and conference participation. The feed provides a single location to follow how MindWalk applies its HYFT and LensAI technologies across influenza, dengue, GLP-1 and neurodegenerative programs, alongside updates on its financial performance and strategic structure.
MindWalk Holdings (Nasdaq: HYFT) reported Q3 fiscal 2026 revenue of $4.2 million, a 52% increase year‑over‑year, marking the third consecutive quarterly YoY revenue gain. US revenue doubled to $2.6 million. Gross margin was 59% in Q3 and cash totaled $14.2 million as of Jan 31, 2026.
The company signed its first one‑year recurring LensAI platform contract, launched the B cell Llama nanobody platform, reported progress on dengue, GLP‑1 and influenza programs, and is designing asset‑level financing for select assets.
MindWalk Holdings (NASDAQ: HYFT) announced B Cell Llama™, a VHH nanobody discovery platform built for bispecific, multispecific and cell therapy development. A peer-reviewed 2026 study in Biomacromolecules showed multivalent VHH formats reached sub-nanomolar potency and 10–25x activity versus monovalent forms.
The study found a trivalent construct neutralized variants that escaped monovalent molecules and suggested a possible immune-priming effect. MindWalk holds first right to commercialize jointly developed IP and will layer LensAI™ to prioritize functional activity over binding metrics.
MindWalk Holdings Corp (NASDAQ:HYFT) will report third quarter fiscal 2026 results and host a live conference call and webcast on March 12, 2026 at 10:30 AM ET. Financial results will be released prior to the call and followed by a management presentation and Q&A.
Live and replay access will be available via the company’s investor events page, with participant dial-in details and conference ID provided for telephone access.
MindWalk (NASDAQ:HYFT) applied its proprietary HYFT® functional‑intelligence technology to detect “functional adjacency” — distinct molecules that produce the same therapeutic effect despite low sequence similarity. Using an influenza study, HYFT identified a conserved biological signature that persists across viral mutation, supporting broader vaccine target design and exposing competitive/IP risks that sequence alignment can miss. MindWalk positions HYFT as a scalable platform to assess functional overlap for discovery, diligence, patent strategy, and portfolio risk as AI accelerates protein design.
MindWalk (Nasdaq: HYFT) announced discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in ALS, frontotemporal dementia and some Alzheimer’s disease cases. The work shows the company’s platform can distinguish toxic protein conformations from healthy forms and anchors those findings with bio-native wet-lab validation. MindWalk says this validates its platform strategy and reinforces its position as a discovery partner for complex neurodegenerative programs. The study is available on bioRxiv (DOI: 10.1101/2025.06.10.658846).
MindWalk (NASDAQ:HYFT) reports a functional insight in its universal influenza program: a HYFT-defined functional constraint observed across influenza A and B despite sequence variation. MindWalk says this pattern was validated in human H3N2 (including subclade K), avian H5/H7/H9, swine H1N1, and influenza B (Victoria and Yamagata). The company plans further pre-clinical validation and IND-enabling work within a segregated program portfolio, then aims to out-license or partner for late-stage development.
MindWalk (NASDAQ:HYFT) announced a discovery of a persistent functional constraint in influenza biology identified using its patented HYFT Deep Data technology. The company reports the HYFT-defined pattern is conserved across human influenza A (including H3N2 and H3N2 subclade K), avian A subtypes H5, H7, H9, swine-origin H1N1, and influenza B lineages Victoria and Yamagata. MindWalk says this constraint reflects biophysical requirements for infection rather than conserved sequence, and plans further preclinical and IND-enabling work with an out-licensing or strategic-partnering strategy for the program.
MindWalk (NASDAQ: HYFT) reported Q2 fiscal 2026 results and strategic progress on its AI-driven pipeline on December 15, 2025. Key financials: Revenue $4.1M (+54% YoY, +30% sequential), gross margin 65% (from 51%), gross profit $2.7M (+94% YoY), adjusted EBITDA loss improved to $2.4M, and operating loss excluding amortization improved to $2.8M. Cash and cash equivalents were $16.5M, including proceeds from the sale of Netherlands operations.
Strategic updates: AI-designed GLP1 receptor agonist showed in vitro activation above semaglutide; a companion longevity pathway was identified; a conserved dengue epitope was discovered with preclinical planning underway; the company completed a rebrand, appointed a new CFO and CBO, closed a Netherlands divestiture for $14.3M, and initiated a Cayman structure to ringfence AI program portfolios with investor interest ahead of a January 12, 2026 strategic update.
MindWalk Holdings (NASDAQ:HYFT) will release second quarter fiscal 2026 financial results and host a live webcast and conference call on December 15, 2025 at 10:30 AM ET.
The company said a press release with the quarterly financial results will be issued prior to the call, followed by management remarks and a question-and-answer session. The live webcast and replay will be available via the company investor events page and an attendee URL is provided for access.
Dial-in numbers and a conference ID are provided for participants; investors are encouraged to review the company's periodic reports on sec.gov and sedarplus.com for risk factors and historical results.
MindWalk (Nasdaq: HYFT) announced that CTO Dr. Dirk Van Hyfte will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025 on November 20, 2025, 12:15 PM–12:45 PM. Dr. Van Hyfte will discuss how MindWalk’s HYFT®-powered LensAi™ platform indexes, connects, and continuously updates biological knowledge to support AI-driven drug discovery. The company frames the appearance as an opportunity to share its Bio-Native AI approach and Deep Data capabilities with industry peers and researchers.